about
The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.Effect of oral glucose administration on rebound growth hormone release in normal and obese women: the role of adiposity, insulin sensitivity and ghrelin.Clinical manifestations and diagnosis of acromegalyTesticular expression of the Lin28/let-7 system: Hormonal regulation and changes during postnatal maturation and after manipulations of puberty.Hypopituitarism due to lymphocytic hypophysitis in a patient with retroperitoneal fibrosisFNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle.Ghrelin and lipid metabolism: key partners in energy balance.Ghrelin in obesity, physiological and pharmacological considerations.Acute changes in free-fatty acids (FFA) do not alter serum leptin levels.Ghrelin neutralization during fasting-refeeding cycle impairs the recuperation of body weight and alters hepatic energy metabolism.Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome.Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion.Importance of exercise in the control of metabolic and inflammatory parameters at the moment of onset in type 1 diabetic subjects.Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications.Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.Maternal and perinatal outcomes after bariatric surgery: a Spanish multicenter study.[Practical guidelines for diagnosis and treatment of acromegaly. Grupo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición].Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.Fasting and postprandial plasma ghrelin levels are decreased in patients with liver failure previous to liver transplantation.Short-term regulation of peptide YY secretion by a mixed meal or peritoneal glucose-based dialysate in patients with chronic renal failure.Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial.Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.Perturbation of hypothalamic microRNA expression patterns in male rats after metabolic distress: impact of obesity and conditions of negative energy balance.Prevalence, Clinical Features, and Natural History of Incidental Clinically Non-Functioning Pituitary Adenomas.Non-functioning pituitary adenoma underwent surgery: A multicenter retrospective study over the last four decades (1977-2015).Sexual dimorphism on growth hormone secretion after oral glucose administration.Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.Growth Hormone SecretagoguesRecomendaciones diagnósticas y terapéuticas en el sobrepeso y la obesidad durante la adolescenciaEffects of oral glutamine during abdominal radiotherapy on chronic radiation enteritis: A randomized controlled trialFlexion contractures and hypopituitarism[Langerhans-cell histiocytosis with hypothalamus involvement][Different etiology of thyrotoxicosis as a function of previous prevalence of goiter]Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome[Aplastic pancytopenia caused by antithyroid drugs]Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity[A new case of pituitary adenoma commencing with hypothyroidism][Association of thoracic carcinoid tumor and hyperparathyroidism. Presentation of 2 cases][Multiple endocrine neoplasms (MEN I): experience with 15 cases]
P50
Q33633368-3A674F4D-F74D-4C9E-8441-D7E934D8BB68Q35188165-4761C1F6-4A42-4F24-AF15-2B2BAFC65869Q35810485-981E91F5-4CF5-4FEA-84BF-6D6EF43E1A17Q36192983-B0B612F2-B9B0-4939-8722-206431BE75C2Q36728244-B54DCC4D-F1AD-41A4-93C2-0ADAA27244F6Q37105019-5E629819-243F-48F3-B25E-3E95737725E5Q37822218-6E7B00FB-7574-4F96-9F35-274FC949667AQ38038912-1E27F4A5-91AB-4D6A-A670-64D74C694B5AQ38331672-C66C65E7-3C83-498F-80D3-D6C80D9D59D5Q38337998-AA1AB7EA-C6C3-4356-B536-130BAAFF7FA0Q41458821-B3126E46-1185-4919-A2BD-C932830759F9Q42153443-E5A5326A-42BC-4E14-9E95-CBBB436B0DD7Q42458438-8B72238F-028F-4659-801B-64D2B078DB4DQ42672818-57E35516-8A36-4721-B5FA-57153E3977F3Q44311512-F06429A0-23EA-47B5-BA01-71B5F8953078Q44413424-99FF6697-19E8-4184-B534-125564CAAB12Q44454441-0DA54BF8-7A96-4D93-808B-260D8ED6F7BFQ44529963-7176CFB8-1FA6-404D-8AE5-DE7A0C0ED17DQ46052614-446B373C-886D-4052-AE5E-4B2D555F1832Q46575691-12831DB9-5205-45E8-ACFE-0AA1EB86B0D8Q46738218-E3C02601-7B5C-4226-B879-35209AFC9817Q48435086-8E385FC4-9C14-4A1E-AD39-A65AEEB8F007Q50479358-EE92196B-A665-4DDC-8330-A54876911D0DQ50515924-8CCEEDE8-4033-4584-BD78-3B84D12F60C8Q50742593-8E70859C-7446-4FDD-BFFC-73F9FA824876Q51360858-83EBFA44-7F97-4324-8088-E5A983D3B138Q52510599-E4165200-ABA6-4697-AF58-097A4F45EC04Q55349083-002023C6-B8C2-417D-A0DA-61F9EE4BB4BDQ56609521-E640FADE-6F5E-4B16-82B3-061818575B3AQ60729973-69769E91-6D99-45BD-84F8-C331F8070052Q61028767-0357C0C9-E8DE-483F-833B-49DA83BB77E6Q67874362-FC179822-8E8A-4892-B803-11667B5E81DAQ67972329-091510DA-6F4F-460F-A6C6-B1E500CBB36FQ68022166-58846DC6-7958-4545-9B69-F81686A71FCFQ68580028-098ED535-767B-4378-BE9C-37F2F7C1CD5CQ69006310-F2DAE93D-F7C7-4B47-8B37-CAF8340D0BE3Q69178045-DFD89F07-CC4C-4F96-82D9-0AED196C11AFQ69628283-39345465-D968-4681-AF36-5C6579DA17F2Q69882595-ED5350F5-5C29-46FF-9391-BBFEC38E1B4DQ69903294-9756C741-CDD4-4846-92A9-38D606A7F3E5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fernando Cordido
@ast
Fernando Cordido
@en
Fernando Cordido
@es
Fernando Cordido
@nl
type
label
Fernando Cordido
@ast
Fernando Cordido
@en
Fernando Cordido
@es
Fernando Cordido
@nl
prefLabel
Fernando Cordido
@ast
Fernando Cordido
@en
Fernando Cordido
@es
Fernando Cordido
@nl
P106
P31
P496
0000-0003-3528-8174